GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC	hepatocellular carcinoma	Active, not recruiting	Phase 1 / Phase 2	2026-09-24		NCT04251117

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Geneos Therapeutics	3

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Auckland Clinical Studies	Auckland	New Zealand	1
Icahn School of Medicine at Mount Sinai	New York	United States	342
Johns Hopkins Hospital	Baltimore	United States	135

Clinical trials